Elevance Health, Inc.
NYSEElevance Health gave back ground this week, falling 6.3% to $397.80 — erasing the gains that had briefly carried the stock above its consensus mean target and putting options traders on edge just four weeks before the next earnings print. The clearest signal this week is in options. Defensive positioning has jumped to its most elevated reading of the past month, with the put/call…
ELV cost to borrow surges 494% in one week to 0.46%, reflecting sharply elevated short friction as availability remains abundant at 9,858%.
Elevance Health gave back ground this week, falling 6.3% to $397.80 — erasing the gains that had briefly carried the stock above its consensus mean target and putting options traders on edge just four weeks before the…
ELV has staged a sharp recovery this week, but the real story is what's happening on the Street — a wave of analyst target upgrades that has effectively validated the rebound and is still running ahead of where the…
Snapshot as of 5 Jul 2026
Elevance Health arrives at mid-week with its most constructive analyst backdrop in months — and a stock up 24% in a single month that is finally starting to earn its valuation lift. The catalyst shaping this week's…
Elevance Health heads into its May 13 earnings report on the back of a sharp 21% one-month rally and a wave of analyst optimism — leaving the debate squarely about whether the recovery in managed care valuations has…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for ELV — free to start on ORTEX.
Sign up for free →Open ELV on ORTEX